4th European Biotech & Medtech Investor Day

by France Biotech
PHARMALEADS

NAME OF THE CEO
Thierry BOURBIE

ADDRESS
11 rue Watt, 75013, Paris France

EMAIL
info@pharmaleads.com
www.pharmaleads.com

MANAGEMENT TEAM
CEO: Thierry BOURBIE
CFO: Pierre Maillard
VP Medical Affairs, Strategy and BD: Michel Wurm, MD

TARGETED MARKET
Acute pain currently treated by injectable opiates
Chronic neuropathic/inflammatory pain

PRIVATE COMPANY
CREATION DATE
December 2000

MISSION
Pharmaleads develops proprietary new chemical entities to alleviate severe pain, acute or chronic, without the side effects of opiates and other current treatments. Our compounds are ideally positioned to combat the opioid crisis, which costs billions to the United States.

TECHNOLOGY
Pharmaleads DENKIs (Dual Enkephalinase Inhibitors) inhibit enképhalinases, the two enzymes which very rapidly degrade enkephalins, the main endogenous pain modulators, thereby increasing their concentrations and eliciting long-lasting analgesic effects, without the side-effects of exogenous opiates.

COMPETITION
Acute pain: injectable opiates
Chronic pain: gabapentinoids and antidepressants

ALLIANCES/PARTNERSHIPS

Academic partnerships:
- Florence Noble, Saints-Pères Medical School, Paris 5
- Rafael Maldonado, University Pompeu Fabra, Barcelona
- Radhouane Dallel, Neuro-Dol Inserm U1107, Clermont-Ferrand
- Emily Jutkiewicz, University of Michigan
- Stephane Melik-Parsadaniantz, Annabelle Réaux-Le Goazigo, Institut de la Vision, Paris
- Ana Baamonde, University of Oviedo
COMPANY SUMMARY

UPCOMING CATALYSTS

PL265

Q3 2018: Initiation of Multiple Ascending Oral doses Phase 1 study

Q4 2018: Initiation of 6-week oral tox studies in two species

Q3 2018: Initiation of 28-day tolerability/PK studies for eye drops

Q2 2019: Followed by Phase 1/2a clinical study for with eye drops (ocular pain)

PL35 i.v.

Q4 2018: Initiation of 2-week infusion tox studies in two species

Q3 2019: Followed by Phase 1/2a clinical study (healthy volunteers plus post-surgical pain in patients at the end)

Publications

Paper on efficacy of PL265 on ocular pain and inflammation submitted to Pain

Posters

WIP, Dublin May 2018, preclinical results of DENKI

Pain Mechanisms and Therapeutics conference Taormina, June 2018. Results of ophthalmology studies with PL265

ICOO 2018, Boston, June: lack of addictive potential of DENKI

IASP Boston, September 2018: two posters. Effects of PL37 on migraine pain, preclinical results of DENKI

PIPELINE

Phase 2 for PL37 and PL265 planned for 2019